GlycoMimetics has entered into an exclusive worldwide licensing agreement with Pfizer for the advancement of GlycoMimetics’ investigational compound, GMI-1070.
GMI-1070, a pan-selectin inhibitor, is currently in Phase II development for the treatment of vaso-occlusive crisis associated with sickle cell disease.
Go deeper with GlobalData
Pfizer will receive an exclusive worldwide licence for GMI-1070, for vaso-occlusive crisis associated with sickle cell disease and any other diseases for which it may be developed.
GlycoMimetics will continue to advance the ongoing Phase II trial under Pfizer’s oversight, and Pfizer will then undertake further development and commercialisation responsibilities.
In pre-clinical studies, GMI-1070 restored blood flow to affected vessels of sickle cell animals experiencing vaso-occlusive crisis.
GlycoMimetics’ drug is also being evaluated in pre-clinical studies for the treatment of other diseases, including haematologic malignancies, where selectin-mediated cell adhesion and migration is known to play a key role in the disease process.
GMI-1070 has received orphan drug and fast-track status from the US Food and Drug Administration.
